Latest Quarterly Sales News

Freehill Mining reported a transitional quarter marked by a dip in sales due to project cycles but offset by strategic site acquisitions and a successful capital raise. The company is poised for growth with new processing sites and promising magnetite test results.

Metgasco reports a 4% dip in quarterly sales revenue and a 9% drop in production, while launching a Production Uplift Program funded by a $750,000 capital raise. Operational improvements at Odin and Vali fields helped slow the decline.

Echelon Resources finalised its EP145 acquisition and reported a slight dip in production volumes, while Amadeus Basin receipts surged 24% thanks to new wells. The company maintains a strong cash position and is actively reshaping its portfolio for future growth.

ImpediMed Limited reported a record quarter for its SOZO device sales with $6.3 million in contracts, supported by expanded US reimbursement coverage and new funding. Despite stable revenue, the company’s cost-cutting and strategic moves position it well for growth in FY26.

ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.

Vintage Energy reported a modest decline in quarterly sales revenue and production but strengthened its cash position through a fully subscribed capital raising and strategic asset sale agreement. The company also initiated a promising feasibility study on a CO2 liquefaction plant at Nangwarry.

WA Kaolin Limited reports robust production growth and expanding sales, driven by new technical kaolin grades and strong forward orders for FY26.

BPM Minerals has reshaped its portfolio by acquiring the Forelands Gold Project and selling the Claw Gold Project, positioning itself for growth in Western Australia’s gold sector.

Lynas Rare Earths has achieved record quarterly production of key rare earth elements and reported a strong 38% increase in sales revenue, while advancing its Mt Weld expansion and signing strategic MOUs in Malaysia.

Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.

Genetic Signatures reported steady quarterly sales of $4.4 million, reflecting seasonal demand in Australia, while restructuring its US operations to accelerate growth. A new US contract and strategic partnerships signal potential for future expansion.

Immuron Limited reports a robust 49% increase in FY25 global sales of its immune supplement Travelan, driven by strong growth in Australia and North America. The company plans to accelerate its North American market presence in FY26.